Interview
with Neil Love, MD Breast Cancer Update for Medical Oncologists,
Program 6 2000
Play
Audio Below:
What
we found in the laboratory, in experimental animals was that, "Yes,
it is a more potent antiestrogen than either oophorectomy to reduce
the estrogen level or tamoxifen," and that showed up mostly as a
marked prolongation to the time for resistance to develop. So that
in our model, by 100 days, three or four months, many of the tumors
in mice treated with tamoxifen are beginning to re-grow and become
resistant at the start of tamoxifen-stimulated growth. With Faslodex,
it’s over twice as long, the period of time it takes for some
tumors to become resistant. And not all tumors do. We’ve had
some tumors – maybe 15 or 20 percent of the tumors – that
never started to re-grow on Faslodex, and some of those we’ve
biopsied the area where the tumor was and there’s no viable
tumor. We’ve never seen that with any other endocrine therapy.
It suggests that maybe in this model, Faslodex can even cure some
of the mice.
So,
we found that it’s a more potent antiestrogen, a more potent
anti-tumor inhibitor and, when we used it in tumors that were being
stimulated by tamoxifen, it inhibited those. So, we hypothesized
it would work in tamoxifen-resistant patients.
Similarities
and distinctions in the mode of action of different classes of antioestrogens
[Review]. Wakeling,
A. E. Endocrine-Related Cancer. 7(1):17-28, 2000 Mar. No abstract
Approaches
targeted to estrogen receptors for treatment of tamoxifen-resistant
breast cancer: A brief overview. Terakawa, N. (Reprint available from: Terakawa N Tottori Univ,
Sch Med, Dept Obstet & Gynecol Yonago Tottori 683 Japan)..
Oncology. 59(Suppl 1):3-4, 2000. No abstract
Treatment
with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis
factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells. Smolnikar,
K.; Loffek, S.; Schulz, T.; Michna, H., and Diel, P. (Reprint available
from: Smolnikar K DSHS Cologne, Inst Morphol & Tumor Res Carl
Diem Weg 6 D-50927 Cologne Germany). Breast Cancer Research &
Treatment. 63(3):249-259, 2000 Oct. In process
Symposium
overview: Estrogens and antiestrogens in managing the patient with
breast cancer. Newman,
L. A.; Wood, W. C.; Sellin, R. V.; Morrow, M.; Vogel, C., and Singletary,
S. E (Reprint available from: Singletary SE Univ Texas, MD Anderson
Canc Ctr, Dept Surg Oncol 1515 Holcombe Blvd,Box 106 Houston, TX
77030 USA).. Annals of Surgical Oncology. 7(8):568-574, 2000 Sep.
In process
